e-learning
resources
Milan 2017
Tuesday, 12.09.2017
IPF: from the bench to the bedside
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Effect of nintedanib on multidimensional evaluation in patients with IPF
K. Kataoka (Seto, Aichi, Japan)
Source:
International Congress 2017 – IPF: from the bench to the bedside
Session:
IPF: from the bench to the bedside
Session type:
Thematic Poster
Number:
3810
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
K. Kataoka (Seto, Aichi, Japan). Effect of nintedanib on multidimensional evaluation in patients with IPF. 3810
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Effect of nintedanib on blood biomarkers in patients with IPF in the INMARK trial
Source: International Congress 2019 – Biomarkers and beyond in idiopathic interstitial pneumonia
Year: 2019
Evaluation of treatment with Nintedanib in patients with idiopathic pulmonary fibrosis: a proteomical approach
Source: International Congress 2019 – Innovations in idiopathic pulmonary fibrosis
Year: 2019
Changes in biomarkers with nintedanib plus sildenafil in subjects with IPF by presence of emphysema in the INSTAGE trial
Source: Virtual Congress 2020 – Promising biomarkers for idiopathic interstitial pneumonia
Year: 2020
Effects of Hochuekkito combined with pulmonary rehabilitation in patients with COPD
Source: International Congress 2017 – Latest insights into pulmonary rehabilitation in COPD
Year: 2017
Efficacy and safety of combined use of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis
Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia
Year: 2021
Efficacy and safety of nintedanib in the elderly patient with IPF
Source: International Congress 2019 – Treatment and prognosis of idiopathic interstitial pneumonia
Year: 2019
Effect of metformin on clinically relevant outcomes in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2017 – ILDs: clinical aspects
Year: 2017
Clinical and functional effectiveness of roflumilast in severe COPD patients
Source: Annual Congress 2013 –Modern approach to various clinical settings
Year: 2013
Concomitant medications and efficacy of nintedanib in patients with IPF
Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside
Year: 2017
Efficiency of different multidimensional indexes for the assessment of the risk of exacerbations in patients with COPD
Source: Virtual Congress 2020 – Prediction of outcomes in obstructive diseases
Year: 2020
Effects of NAC on outcome variables in COPD patients
Source: Eur Respir J 2004; 24: Suppl. 48, 14s
Year: 2004
Long-term safety of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF): Pooled analysis of 4 clinical trials
Source: International Congress 2016 – IPF treatment I
Year: 2016
Effects of roflumilast in highly symptomatic COPD patients
Source: Annual Congress 2012 - Effectiveness of therapeutic interventions in primary care
Year: 2012
The clinico-immunological evaluation of the ribomunyl therapy in complex treatment of COPD patients
Source: Eur Respir J 2006; 28: Suppl. 50, 674s
Year: 2006
Long-term safety of combination therapy with nintedanib and pirfenidone in Japanese patients with IPF
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
Real-life comparison between pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis
Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia
Year: 2021
Changes in biomarkers in patients with idiopathic pulmonary fibrosis (IPF) treated with nintedanib and sildenafil
Source: International Congress 2019 – The evolving field of idiopathic interstitial pneumonia
Year: 2019
Responsiveness of different multidimensional severity indices to pulmonary rehabilitation in patients with COPD
Source: Annual Congress 2012 - Physiotherapy and rehabilitative interventions applied to different populations with respiratory impairment
Year: 2012
Effect of pulmonary rehabilitation on EuroQoL in COPD patients
Source: Annual Congress 2008 - Impact of rehabilitation programmes in COPD and non-COPD patients
Year: 2008
Effect of long-term treatment with fenspiride on clinical and functional status of patients with chronic obstructive pulmonary disease
Source: Annual Congress 2010 - COPD: management
Year: 2010
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept